The Effect of Time-Restricted Feeding on Body Composition and Some Metabolic Parameters in Obese Adolescents
1 other identifier
interventional
60
1 country
1
Brief Summary
Obesity is now recognized as a serious public health problem. It is known that obesity seen in adolescence is largely carried over to adulthood. Therefore, its treatment is important both in terms of protecting current health and preventing diseases in adulthood. Reducing energy intake plays an important role in the treatment of obesity. However, long-term adherence and effectiveness to energy restriction appear to be limited. Therefore, the need for interventions that are "effective in body weight loss" and "accessible, simple and lifestyle modification to increase dietary compliance" is clear. Time-restricted feeding is a specialized intermittent fasting protocol that includes consistent fasting and eating periods over a 24-hour cycle by supporting circadian rhythms. Especially in the adult population, positive effects of time-restricted feeding such as weight loss and blood glucose regulation are observed. However, there are limited data on this subject for adolescents. Today, the Mediterranean diet, which is one of the nutrition models that supports health, is a beneficial nutritional model that reduces body weight and obesity-related comorbidities by limiting total energy intake. However, no study has been found in the literature in which the effectiveness of time-restricted nutrition, which is a new and promising approach, and the Mediterranean diet, which is a sustainable diet model, are evaluated together. Therefore, in this study, it was aimed to evaluate the effects of planned time-restricted nutrition compatible with circadian rhythm and energy-restricted feeding planned according to the Mediterranean diet model on body composition and various metabolic parameters in obese adolescents. 60 obese adolescents aged 12-18 years will be included in this randomized controlled and parallel design study. Participants will be randomized to one of two treatment groups for a 12-week intervention. The time-restricted feeding group will form the intervention group of the study, and the energy-restricted feeding group will form the control group. Anthropometric measurements of the participants at the beginning and end of the study will be taken, and various biochemical parameters will be evaluated with the body composition and blood samples to be taken. As a result of the study, it is expected to determine the effectiveness of time-restricted feeding compared to energy-restricted feeding in terms of dietary compliance, body composition and biochemical changes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 11, 2024
CompletedFirst Posted
Study publicly available on registry
September 27, 2024
CompletedStudy Start
First participant enrolled
October 14, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2025
CompletedFebruary 25, 2025
February 1, 2025
7 months
September 11, 2024
February 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Changes in body weight
Changes in body weight will be examined as a result of the implemented nutrition plan.
Baseline, Week 4, Week 8 and Week 12
Changes in body fat percentage
Changes in body fat percentage as a result of the implemented nutrition plan will be examined. The fat percentage will be assessed based on measurements taken with bioimpedance analysis devices.
Baseline, Week 4, Week 8 and Week 12
Changes in body mass index
Changes in body mass index as a result of the implemented nutrition plan will be examined. Body mass index (BMI) will be calculated based on changes in height (cm) and weight (kg) values, using the formula kg/m².
Baseline, Week 4, Week 8 and Week 12
Biochemical changes
As a result of the implemented nutrition plan, changes in fasting glucose (mg/dL), total cholesterol (mg/dL), LDL cholesterol (LDL-C; mg/dL), HDL cholesterol (HDL-C; mg/dL), and triglycerides (mg/dL) levels will be evaluated.
Baseline and Week 12
Changes in glycated hemoglobin levels
As a result of the implemented nutrition plan, changes in glycated hemoglobin (HbA1c) levels will be evaluated.
Baseline and Week 12
Changes in insulin levels
As a result of the implemented nutrition plan, changes in insulin levels (measured in µIU/mL) will be evaluated.
Baseline and Week 12
Changes in hormone levels
At the conclusion of the implemented nutrition plan, changes in the levels of leptin, ghrelin, adiponectin, irisin, and nesfatin hormones (ng/mL) will be evaluated.
Baseline and Week 12
Changes in inflammatory markers
At the conclusion of the implemented nutrition plan, changes in various inflammation markers, including interleukin (IL)-17, IL-10, IL-6, IL-1β, and TNF-α (ng/mL), will be evaluated.
Baseline and Week 12
Study Arms (2)
Control group - Calorie-restricted feeding
EXPERIMENTALParticipants will be applied a nutrition plan prepared in line with the principles of the Mediterranean Diet without any time restrictions.
Intervention group - Time restricted feeding
EXPERIMENTALParticipants will be applied with an ad libitum nutrition plan between 10:00 and 18:00.
Interventions
Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
Eligibility Criteria
You may qualify if:
- Adolescents aged 12-18 with puberty stage:5
- Obese adolescents with a metabolic disorder (such as fatty liver, insulin resistance, prediabetes, dyslipidemia) (BMI≥95th percentile for age)
- Those who have a stable body weight for 3 months before the start of the study (current weight gain or loss \<4 kg)
- Those who own and can use a Smartphone with Apple iOS or Android operating system
- Those who speak, read and understand Turkish
You may not qualify if:
- Those with any endocrine disorder, metabolic, chronic or major psychiatric disease other than obesity, insulin resistance, dyslipidemia, prediabetes, fatty liver
- Polycystic ovary syndrome (PCOS)
- Those with physical or mental disabilities
- Those with allergies, intolerances or eating disorders
- Those who smoke and drink alcohol
- Use of drugs that may affect study results, circadian rhythms or metabolism (such as antidiabetics, steroids, beta blockers, adrenergic stimulating agents, laxatives, etc.)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sümeyra Başarlead
- Health Institutes of Turkeycollaborator
Study Sites (1)
Mustafa Eraslan and Fevzi Mercan Children's Hospital
Kayseri, 38039, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Sümeyra Başar
sumeyra_akalin@hotmail.com
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- project manager
Study Record Dates
First Submitted
September 11, 2024
First Posted
September 27, 2024
Study Start
October 14, 2024
Primary Completion
May 15, 2025
Study Completion
August 15, 2025
Last Updated
February 25, 2025
Record last verified: 2025-02